Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: 360iResearch | PRODUCT CODE: 1586002

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1586002

COVID-19 Vaccines Market by Product Type (Monovalent Vaccine, Multivalent Vaccine), End-User (Academic & Research Centers, Clinics, Hospitals), Patient Type - Global Forecast 2025-2030

PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

Description

Table of Contents

List of Tables

The COVID-19 Vaccines Market was valued at USD 215.43 billion in 2023, expected to reach USD 237.12 billion in 2024, and is projected to grow at a CAGR of 10.55%, to USD 434.83 billion by 2030.

The market research scope for COVID-19 vaccines encompasses the analysis of trends, market dynamics, and consumer behavior associated with vaccine development, distribution, and adoption. The necessity of these vaccines is imperative for global public health, aiming to mitigate the spread of the virus and reduce mortality rates, which directly influences economic recovery and societal well-being. The application of COVID-19 vaccines includes widespread immunization across demographic groups, addressing variants, and potential booster doses, with their end-use spanning the general public, healthcare sectors, and government and private entities. Market insights reveal key growth factors such as ongoing governmental support, a surge in public awareness, and advancements in mRNA technology that underpin vaccine innovation. However, emerging opportunities lie in expanding vaccine access to underserved regions through partnerships with international health organizations and improving supply chain logistics. These opportunities can be capitalized on by leveraging technological advancements and strategic alliances to bolster distribution networks. Limitations include vaccine hesitancy driven by misinformation, regulatory hurdles, and logistical challenges in storage and distribution, particularly in remote areas. Additionally, the virus's evolving nature and the emergence of new variants pose challenges that could alter vaccine efficacy and demand continuous research and adaptation. To navigate these challenges, businesses can innovate in areas such as vaccine storage technology, blockchain for supply chain management, and AI-driven research for adaptive vaccine formulations. The market is characterized by rapid advancements and intense competition, with players continuously seeking to enhance their offerings and expand their regional presence. Collaborations between pharmaceutical companies and tech firms could drive significant advancements in vaccine development and distribution efficiency, providing a comprehensive approach to combating COVID-19 and its evolving threats.

KEY MARKET STATISTICS
Base Year [2023] USD 215.43 billion
Estimated Year [2024] USD 237.12 billion
Forecast Year [2030] USD 434.83 billion
CAGR (%) 10.55%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COVID-19 Vaccines Market

The COVID-19 Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rapid spread of coronavirus resulting in a large number of deaths
    • Government support and grants for COVID-19 vaccines
    • Increasing research and development (R&D) initiatives for vaccines
  • Market Restraints
    • Limited supportive infrastructure, skills, and technology in developing areas around the world
  • Market Opportunities
    • Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
    • Rising investments for vaccines
  • Market Challenges
    • Side effects associated with the COVID-19 vaccines

Porter's Five Forces: A Strategic Tool for Navigating the COVID-19 Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COVID-19 Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COVID-19 Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COVID-19 Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COVID-19 Vaccines Market

A detailed market share analysis in the COVID-19 Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COVID-19 Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COVID-19 Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the COVID-19 Vaccines Market

A strategic analysis of the COVID-19 Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the COVID-19 Vaccines Market, highlighting leading vendors and their innovative profiles. These include AIVITA Biomedical Inc., AstraZeneca PLC, Baseimmune Ltd., Bharat Biotech International Ltd., Biological E. Ltd., CanSino Biologics Inc., Centivax Inc., Codagenix Inc., CureVac SE, Dr. Reddy's Laboratories Ltd., Emergex Vaccines Holding Ltd., Etherna Immunotherapies NV, Gennova Biopharmaceuticals Ltd., GlaxoSmithKline PLC, HDT Bio, Inc., Meissa Vaccines, Inc., Merck & Co., Inc., Moderna, Inc., Novavax Inc., Osivax SAS, Pfizer Inc., Providence Therapeutics Inc., SANOFI, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Vaccitech PLC, and Zydus Lifesciences Ltd..

Market Segmentation & Coverage

This research report categorizes the COVID-19 Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on End-User, market is studied across Academic & Research Centers, Clinics, Hospitals, and Vaccination Centers.
  • Based on Patient Type, market is studied across Adult, Pediatric, and Senior Citizens.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Show more
Product Code: MRR-02026C4C976F

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rapid spread of coronavirus resulting in a large number of deaths
      • 5.1.1.2. Government support and grants for COVID-19 vaccines
      • 5.1.1.3. Increasing research and development (R&D) initiatives for vaccines
    • 5.1.2. Restraints
      • 5.1.2.1. Limited supportive infrastructure, skills, and technology in developing areas around the world
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing amalgamation activities to manufacture and distribute the COVID-19 vaccines
      • 5.1.3.2. Rising investments for vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the COVID-19 vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COVID-19 Vaccines Market, by Product Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. COVID-19 Vaccines Market, by End-User

  • 7.1. Introduction
  • 7.2. Academic & Research Centers
  • 7.3. Clinics
  • 7.4. Hospitals
  • 7.5. Vaccination Centers

8. COVID-19 Vaccines Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Pediatric
  • 8.4. Senior Citizens

9. Americas COVID-19 Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific COVID-19 Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa COVID-19 Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AIVITA Biomedical Inc.
  • 2. AstraZeneca PLC
  • 3. Baseimmune Ltd.
  • 4. Bharat Biotech International Ltd.
  • 5. Biological E. Ltd.
  • 6. CanSino Biologics Inc.
  • 7. Centivax Inc.
  • 8. Codagenix Inc.
  • 9. CureVac SE
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Emergex Vaccines Holding Ltd.
  • 12. Etherna Immunotherapies NV
  • 13. Gennova Biopharmaceuticals Ltd.
  • 14. GlaxoSmithKline PLC
  • 15. HDT Bio, Inc.
  • 16. Meissa Vaccines, Inc.
  • 17. Merck & Co., Inc.
  • 18. Moderna, Inc.
  • 19. Novavax Inc.
  • 20. Osivax SAS
  • 21. Pfizer Inc.
  • 22. Providence Therapeutics Inc.
  • 23. SANOFI
  • 24. Serum Institute of India Pvt. Ltd.
  • 25. Sinovac Biotech Ltd.
  • 26. Vaccitech PLC
  • 27. Zydus Lifesciences Ltd.
Show more
Product Code: MRR-02026C4C976F

LIST OF FIGURES

  • FIGURE 1. COVID-19 VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. COVID-19 VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COVID-19 VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COVID-19 VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COVID-19 VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 VACCINES MARKET SIZE, BY SENIOR CITIZENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES COVID-19 VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA COVID-19 VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM COVID-19 VACCINES MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. COVID-19 VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. COVID-19 VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!